Dr. Zelenetz on Nivolumab Plus Ibrutinib in Patients With CLL

Andrew D. Zelenetz, MD, PhD
Published: Tuesday, Apr 25, 2017



Andrew D. Zelenetz, MD, PhD, medical director of Quality Informatics at Memorial Sloan Kettering Cancer Center, discusses an early-phase trial of nivolumab (Opdivo) plus ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia (CLL).

A clinical trial of nivolumab combined with ibrutinib was explored in patients with CLL and Richter’s transformation. However, results showed that all of the clinical activity observed with nivolumab was in patients who had Richter’s transformation, but not CLL. The activity observed is what would have been expected ibrutinib to have in patients with CLL.  
SELECTED
LANGUAGE


Andrew D. Zelenetz, MD, PhD, medical director of Quality Informatics at Memorial Sloan Kettering Cancer Center, discusses an early-phase trial of nivolumab (Opdivo) plus ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia (CLL).

A clinical trial of nivolumab combined with ibrutinib was explored in patients with CLL and Richter’s transformation. However, results showed that all of the clinical activity observed with nivolumab was in patients who had Richter’s transformation, but not CLL. The activity observed is what would have been expected ibrutinib to have in patients with CLL.  



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Addressing Post-Transplant Obstacles: Current and Emerging Strategies to Evolve the Standard of Care for Patients With Graft-Versus-Host DiseaseMar 28, 20192.0
2017 Year in Review™: Clinical Impact of Immunotherapies in the Treatment of CancerMar 30, 20191.75
Publication Bottom Border
Border Publication
x